Drugs / MBS303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05806099 | Jun 2023 → Nov 2025 overdue | non-Hodgkin lymphoma | Beijing Mabworks Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBS303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05806099 ↗ |
| Modality | Protein / enzyme biologic | “a novel T-Cell bispecific (TCB), MBS303” NCT05806099 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT05806099 ↗ |